Last close As at 15/08/2026
GBP3.96
▲ −0.50 (−0.13%)
Market capitalisation
GBP88m
Content on this client is only available to investors based in the UK.
Please use the tick box below to confirm your location.
Investment Companies
Investment Companies
Bionomics announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-traumatic stress disorder (PTSD). The RESTORE clinical study completed the treatment phase on time and the company stated that it intends to provide topline data by the end of calendar Q318.